Most frequently reported impacts:
- Waking up to urinate (n=30, 100.0%)
- Embarrassment/shame (n=24, 80.0%)
- Lack of control (n=25, 76.7%)
- Stress/anxiety (n=23, 76.7%)
- Worry/concern (n=22, 73.3%)

Most bothersome symptom was sleep deprivation (n=5, 16.7%) with an average rating of 8.9 (scale of 0-10) followed by bathroom mapping (n=4, 13.3%) with an average rating of 6.9.

Recommendations were made to create a tool for a more accurate assessment of overactive bladder (OAB) which includes patient-reported outcomes (PROs) questions, such as Health-Related Quality of Life (HRQoL), patient satisfaction, and adverse events, in addition to symptoms measurement.

A comprehensive patient-completed Bladder Assessment Tool (BAT) is being developed to be used as a primary endpoint in OAB trials with the potential to also monitor patient benefit from treatment in clinical practice.

DISCLOSURE

This study was funded by Astellas Pharma. Christopher R. Chapple is a consultant, researcher, speaker and trial participant for Allergan, Astellas, and Recordati. Con J. Kelleher is a consultant and speaker for Astellas. Emad Siddiqui is Senior Medical Director, Global Medical Affairs Lead Urology at Astellas. Christopher Evans, Zoe Kopp, and Nate Johnson of Endpoint Outcomes are consultants for Astellas.